Abstract
The identification of drug combinations as alternatives to single-agent therapeutics has traditionally been a slow, largely manual process. In the last 10 years, high-throughput screening platforms have been developed that enable routine screening of thousands of drug pairs in an in vitro setting. In this chapter, we describe the workflow involved in screening a single agent versus a library of mechanistically annotated, investigation, and approved drugs using a full dose-response matrix scheme using viability as the readout. We provide details of the automation required to run the screen and the informatics required to process data from screening robot and subsequent analysis and visualization of the datasets.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Borisy AA et al (2003) Systematic discovery of multicomponent therapeutics. Proc. Nat. Acad. Sci 100:7977–7982
Lehár J et al (2007) Chemical combination effects predict connectivity in biological systems. Mol Sys Bio 3:80
Lehár J et al (2009) Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat. Biotech. 27:659–666
Bansal M et al (2014) A community computational challenge to predict the activity of pairs of compounds. Nat. Biotech. 32:1213–1222
Attene-Ramos M et al (2013) The Tox21 robotic platform for the assessment of environmental chemicals—from vision to reality. Drug Discov Today 18:716–723
Yasgar A, Shinn P, Jadhav A et al (2008) Compound management for quantitative high-throughput screening. JALA 13:79–89
Hafner M et al (2016) Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs. Nat Meth 13:521–527
Heske CM et al (2017) Matrix screen identifies synergistic combination of PARP inhibitors and nicotinamide phosphoribosyltransferase (NAMPT) inhibitors in Ewing sarcoma. Clin Cancer Res 23(23):7301–7311
Malo N, Hanley J, Cerquozzi S, Pelletier J, Nadon R (2006) Statistical practice in high-throughput screening data analysis. Nat Biotech 24:167–175
Zhang XD (2007) A pair of new statistical parameters for quality control in RNA interference high-throughput screening assays. Genomics 89:552–561
Chen L et al (2016) mQC: a heuristic quality-control metric for high-throughput drug combination screening. Sci Rep 6:37741
Borisy AA et al (2003) Systematic discovery of multicomponent therapeutics. Proc. Natl. Acad. Sci 100:7977–7982
Schindler M (2017) Theory of synergistic effects: hill-type response surfaces as ‘null-interaction’ models for mixtures. Theor Biol Med Model 14:15
Cokol M et al (2011) Systematic exploration of synergistic drug pairs. Mol Syst Biol 7:544
Acknowledgments
We would like to thank Lesley Mathews-Griner, John Keller, and Don Liu for their contributions to the development of the NCATS combination screening platform.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Shinn, P. et al. (2019). High-Throughput Screening for Drug Combinations. In: Larson, R., Oprea, T. (eds) Bioinformatics and Drug Discovery. Methods in Molecular Biology, vol 1939. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-9089-4_2
Download citation
DOI: https://doi.org/10.1007/978-1-4939-9089-4_2
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-9088-7
Online ISBN: 978-1-4939-9089-4
eBook Packages: Springer Protocols